Shots:

• Eagle to receive royalties increased from 25% to 30% on sales of Bendeka in the US and will keep increasing by 1% until it reaches 32%- on every Oct 1-2019. The US royalty term is set to expire in 2033 from 2025
• Additionally- the restructuring includes Eagle to manufacture Bemdeka for the US market and has agreed to contribute a portion of litigation expense. In 2015- Eagle and Teva enter into a license agreement to commercialize Bendeka (formely Treanda) for CLL and NHL
• Bendeka (bendamustine hydrochloride) a liquid- low-volume (50 mL) and short-time 10-minute infusion formulation has been approved by FDA for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) and has also received Orphan drug Designation from FDA 

Ref: BusinessWire | Image: Twitter